| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -5,502 | -4,028 |
| Proceeds from maturities of marketable debt securities | - | 0 |
| Purchase of marketable debt securities | - | 0 |
| Proceeds from sale of assets | 320 | - |
| Net cash provided by investing activities | 320 | 0 |
| Gross proceeds from private placement of preferred stock and common stock warrants | 3,300 | 3,300 |
| Net proceeds from public offering of common stock and warrants | - | 0 |
| Transaction costs paid pursuant to private placement | 29 | 29 |
| Net proceeds from exercise of warrants | 64 | - |
| Payments of finance lease liability principal | 2 | 2 |
| Net cash provided by financing activities | 3,333 | 3,269 |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | -1,849 | -759 |
| Cash and cash equivalents at beginning of period | 7,534 | - |
| Cash and cash equivalents at end of period | 5,685 | - |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)